Skip to main content
. Author manuscript; available in PMC: 2018 Jul 23.
Published in final edited form as: J Allergy Clin Immunol Pract. 2017 Oct 31;6(4):1287–1296.e1. doi: 10.1016/j.jaip.2017.09.004

Figure 2. IFN-γ release ELISpot and CD137 T-cell activation over time in SCAR patients.

Figure 2

A. IFN-γ release ELISpot for three patients with positive timepoint 1 results and subsequent timepoints.

B. CD137 T cell activation by flow cytometry of the three patients with positive timepoint 1 results above.

Abbreviations: PIP-TAZ, piperacillin-tazobactam; CEF, ceftriaxone; TEN, toxic epidermal necrolysis; SFU, spot forming units; DRESS, drug reaction with eosinophilia system symptoms.

Demonstration of IFN-y release responses in patients with an initial positive result (> 50 SFU/million cells) with a subsequent bleed at least 9 months’ post SCAR onset.

Timepoints post SCAR onset: S1 DRESS (Timepoint 1, 66 days; Timepoint 2, 548 days)

S2 DRESS (Timepoint 1, 312 days; Timepoint 2, 556 days)

S6 DRESS (Timepoint 1, 4 days; Timepoint 2, 286 days)